Cargando…
Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes
INTRODUCTION: Cannabis products have become easily available and accessible after decriminalization of cannabis for recreational and medicinal use in many states. Cannabidiol (CBD) has been of increasing interest to patients and is being used to self-medicate a variety of ailments. However, very lim...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107012/ https://www.ncbi.nlm.nih.gov/pubmed/33981161 http://dx.doi.org/10.2147/JPR.S278718 |
_version_ | 1783689875577372672 |
---|---|
author | Schilling, Jan M Hughes, Chloe G Wallace, Mark S Sexton, Michelle Backonja, Miroslav Moeller-Bertram, Tobias |
author_facet | Schilling, Jan M Hughes, Chloe G Wallace, Mark S Sexton, Michelle Backonja, Miroslav Moeller-Bertram, Tobias |
author_sort | Schilling, Jan M |
collection | PubMed |
description | INTRODUCTION: Cannabis products have become easily available and accessible after decriminalization of cannabis for recreational and medicinal use in many states. Cannabidiol (CBD) has been of increasing interest to patients and is being used to self-medicate a variety of ailments. However, very limited information is available to patients and providers to form an educated opinion regarding its indicated use to treat the many conditions this substance has been implied to be helpful for. The aim of this survey was to learn about participants’ attitudes and views towards cannabis-based medicine (CBM) with a focus on perception of “CBD” and its potential role for pain management. MATERIALS AND METHODS: We recruited survey participants from seven pain management clinics in Southern California to learn about their knowledge, beliefs, and personal experience with CBD products. After Institutional Review Board (IRB) review, an internet survey platform was utilized to administer the survey online. RESULTS: A total of 253 participants answered the survey. Participants were 45.4 ± 13.8 (Mean ± SD) years of age, the majority identified as white (56.1%), had an annual household income of less than $20,000, and were primarily insured by Medicare (22.5%) or Medicaid (43.9%). Among participants, 62.0% reported trying a CBD product [including products containing delta-9-tetrahydrocannabinol (THC)]. The majority responded that these products have helped their pain (59.0%) and allowed them to reduce their pain medications (67.6%), including opioids (53.7%). They reported believing that CBD was a good treatment option (71.1%), not harmful (74.9%), and not addictive (65.3%). About half of participants (51.9%) report that they would be more comfortable with their physician prescribing CBD products. The overall attitude and experience of participants regarding CBD is reported as positive, while 91.9% of people expressed a desire to learn more about it. SUMMARY: In summary, most participants expressed a positive attitude about CBD products as a treatment option, reported positive outcomes when used for multiple different conditions, and would prefer to obtain information about and prescription for CBD from their physicians. |
format | Online Article Text |
id | pubmed-8107012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81070122021-05-11 Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes Schilling, Jan M Hughes, Chloe G Wallace, Mark S Sexton, Michelle Backonja, Miroslav Moeller-Bertram, Tobias J Pain Res Original Research INTRODUCTION: Cannabis products have become easily available and accessible after decriminalization of cannabis for recreational and medicinal use in many states. Cannabidiol (CBD) has been of increasing interest to patients and is being used to self-medicate a variety of ailments. However, very limited information is available to patients and providers to form an educated opinion regarding its indicated use to treat the many conditions this substance has been implied to be helpful for. The aim of this survey was to learn about participants’ attitudes and views towards cannabis-based medicine (CBM) with a focus on perception of “CBD” and its potential role for pain management. MATERIALS AND METHODS: We recruited survey participants from seven pain management clinics in Southern California to learn about their knowledge, beliefs, and personal experience with CBD products. After Institutional Review Board (IRB) review, an internet survey platform was utilized to administer the survey online. RESULTS: A total of 253 participants answered the survey. Participants were 45.4 ± 13.8 (Mean ± SD) years of age, the majority identified as white (56.1%), had an annual household income of less than $20,000, and were primarily insured by Medicare (22.5%) or Medicaid (43.9%). Among participants, 62.0% reported trying a CBD product [including products containing delta-9-tetrahydrocannabinol (THC)]. The majority responded that these products have helped their pain (59.0%) and allowed them to reduce their pain medications (67.6%), including opioids (53.7%). They reported believing that CBD was a good treatment option (71.1%), not harmful (74.9%), and not addictive (65.3%). About half of participants (51.9%) report that they would be more comfortable with their physician prescribing CBD products. The overall attitude and experience of participants regarding CBD is reported as positive, while 91.9% of people expressed a desire to learn more about it. SUMMARY: In summary, most participants expressed a positive attitude about CBD products as a treatment option, reported positive outcomes when used for multiple different conditions, and would prefer to obtain information about and prescription for CBD from their physicians. Dove 2021-05-05 /pmc/articles/PMC8107012/ /pubmed/33981161 http://dx.doi.org/10.2147/JPR.S278718 Text en © 2021 Schilling et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Schilling, Jan M Hughes, Chloe G Wallace, Mark S Sexton, Michelle Backonja, Miroslav Moeller-Bertram, Tobias Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title | Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title_full | Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title_fullStr | Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title_full_unstemmed | Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title_short | Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes |
title_sort | cannabidiol as a treatment for chronic pain: a survey of patients’ perspectives and attitudes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107012/ https://www.ncbi.nlm.nih.gov/pubmed/33981161 http://dx.doi.org/10.2147/JPR.S278718 |
work_keys_str_mv | AT schillingjanm cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes AT hugheschloeg cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes AT wallacemarks cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes AT sextonmichelle cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes AT backonjamiroslav cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes AT moellerbertramtobias cannabidiolasatreatmentforchronicpainasurveyofpatientsperspectivesandattitudes |